UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 248

Sortiert nach

Mechanisms of aromatase inhibitor resistance

Nature reviews. Cancer, 2015-05, Vol.15 (5), p.261

2015

Volltextzugriff (PDF)

Acquired HER2 mutations in ER + metastatic breast cancer confer resistance to estrogen receptor-directed therapies

Nature genetics, 2019-02, Vol.51 (2), p.207-216

2019

Volltextzugriff (PDF)

Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics

Trends in molecular medicine, 2011-02, Vol.17 (2), p.88-96

2011

Volltextzugriff (PDF)

Activating HER2 mutations in HER2 gene amplification negative breast cancer

Cancer discovery, 2013-02, Vol.3 (2), p.224-237

2013

Volltextzugriff (PDF)

Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy

Nature communications, 2021-02, Vol.12 (1), p.733-733, Article 733

2021

Volltextzugriff (PDF)

KSTAR: An algorithm to predict patient-specific kinase activities from phosphoproteomic data

Nature communications, 2022-07, Vol.13 (1), p.4283-4283, Article 4283

2022

Volltextzugriff (PDF)

Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer

Journal of the National Comprehensive Cancer Network, 2019-02, Vol.17 (2), p.141

2019

Volltextzugriff (PDF)

O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer

Nature communications, 2024-07, Vol.15 (1), p.5597-17, Article 5597

2024

Volltextzugriff (PDF)

PI3K Inhibitors in Breast Cancer Therapy

Current oncology reports, 2019-12, Vol.21 (12), p.110-9, Article 110

2019

Volltextzugriff (PDF)

Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer

Oncotarget, 2016-08, Vol.7 (35), p.56864-56875

2016

Volltextzugriff (PDF)

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

Breast cancer research : BCR, 2017-11, Vol.19 (1), p.123-123, Article 123

2017

Volltextzugriff (PDF)

Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis

Breast cancer research : BCR, 2023-10, Vol.25 (1), p.112-112, Article 112

2023

Volltextzugriff (PDF)

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

Journal of clinical oncology, 2012-07, Vol.30 (21), p.2615-2623

2012

Volltextzugriff (PDF)

Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer

Cancer discovery, 2017-10, Vol.7 (10), p.1168-1183

2017

Volltextzugriff (PDF)

Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance

The New England journal of medicine, 2021-09, Vol.385 (13), p.1241-1243

2021

Volltextzugriff (PDF)

Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models

Molecular cancer therapeutics, 2013-08, Vol.12 (8), p.1665-1675

2013

Volltextzugriff (PDF)

Intermittent fasting in the prevention and treatment of cancer

CA: a cancer journal for clinicians, 2021-11, Vol.71 (6), p.527-546

2021

Volltextzugriff (PDF)

RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies

Frontiers in genetics, 2021-02, Vol.11, p.598118-598118

2021

Volltextzugriff (PDF)

Male Breast Cancer: An Updated Surveillance, Epidemiology, and End Results Data Analysis

Clinical breast cancer, 2018-10, Vol.18 (5), p.e997-e1002

2018

Volltextzugriff (PDF)

Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models

Cancers, 2020-12, Vol.12 (12), p.3857

2020

Volltextzugriff (PDF)

Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review

Advances in therapy, 2021-01, Vol.38 (1), p.109-136

2021

Volltextzugriff (PDF)

CDK4/6 inhibition triggers anti-tumour immunity

Nature (London), 2017-08, Vol.548 (7668), p.471-475

2017

Volltextzugriff (PDF)

Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial

Journal of clinical oncology, 2015-01, Vol.33 (3), p.265-271

2015

Volltextzugriff (PDF)

Human aromatase : Gene resequencing and functional genomics

Cancer research (Chicago, Ill.), 2005-12, Vol.65 (23), p.11071-11082

2005

Volltextzugriff (PDF)

Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?

Current oncology reports, 2020-06, Vol.22 (6), p.57-57, Article 57

2020

Volltextzugriff (PDF)

1 – 25 von 248

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(233)
Mit Volltextzugriff
(224)

Publikationsform

Artikel
(246)
Buchkapitel
(1)
Texte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Mechanisms of aromatase inhibitor resistance

Acquired HER2 mutations in ER + metastatic breast cancer confer resistance to estrogen receptor-directed therapies

Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics

Activating HER2 mutations in HER2 gene amplification negative breast cancer

Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy

KSTAR: An algorithm to predict patient-specific kinase activities from phosphoproteomic data

Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer

O-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancer

PI3K Inhibitors in Breast Cancer Therapy

Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer

Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib

Interplay between ESR1/PIK3CA codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (MBC): comprehensive circulating tumor DNA (ctDNA) analysis

TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer

Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer

Breast Cancer, HER2 Mutations, and Overcoming Drug Resistance

Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models

Intermittent fasting in the prevention and treatment of cancer

RNA Based Approaches to Profile Oncogenic Pathways From Low Quantity Samples to Drive Precision Oncology Strategies

Male Breast Cancer: An Updated Surveillance, Epidemiology, and End Results Data Analysis

Proteomic Resistance Biomarkers for PI3K Inhibitor in Triple Negative Breast Cancer Patient-Derived Xenograft Models

Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review

CDK4/6 inhibition triggers anti-tumour immunity

Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial

Human aromatase : Gene resequencing and functional genomics

Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?

Suchergebnisse filtern